Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Panel on cost-effectiveness in health and medicine.

Literature DB >> 8969326

Panel on cost-effectiveness in health and medicine.

M Gold¹.

Abstract

Mesh：

Year: 1996 PMID： 8969326

Source DB: PubMed Journal: Med Care ISSN： 0025-7079 Impact factor: 2.983

Keyword Cloud
Cited

× No keyword cloud information.

55 in total

1. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.

Authors: Chin Hur; Sung Eun Choi; Joel H Rubenstein; Chung Yin Kong; Norman S Nishioka; Dawn T Provenzale; John M Inadomi
Journal: Gastroenterology Date: 2012-05-21 Impact factor: 22.682

2. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.

Authors: Sung Eun Choi; Katherine E Perzan; Angela C Tramontano; Chung Yin Kong; Chin Hur
Journal: Cancer Prev Res (Phila) Date: 2013-12-31

3. Lifetime Economic Burden of Rape Among U.S. Adults.

Authors: Cora Peterson; Sarah DeGue; Curtis Florence; Colby N Lokey
Journal: Am J Prev Med Date: 2017-01-30 Impact factor: 5.043

4. Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis.

Authors: V F Fragoulakis; A G Pallis; D K Kaitelidou; N M Maniadakis; V G Georgoulias
Journal: Lung Cancer (Auckl) Date: 2012-07-16

5. Estimation of lung cancer burden in Australia, the Philippines, and Singapore: an evaluation of disability adjusted life years.

Authors: Suman Morampudi; Neha Das; Arun Gowda; Anand Patil
Journal: Cancer Biol Med Date: 2017-02 Impact factor: 4.248

Panel on cost-effectiveness in health and medicine.

1. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.

2. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.

3. Lifetime Economic Burden of Rape Among U.S. Adults.

4. Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis.

5. Estimation of lung cancer burden in Australia, the Philippines, and Singapore: an evaluation of disability adjusted life years.

6. Improving the quality of abstract reporting for economic analyses in oncology.

Review 7. Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer.

8. Parent Mentors and Insuring Uninsured Children: A Randomized Controlled Trial.

9. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.

10. Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy.